识别与阿尔茨海默氏病早期tau负担相关的认知测试得分
Caitlin M Terao1,2, Madeline Wood Alexander1,3, R Philip Chalmers2
1Hurvitz Brain Sciences Program Sunnybrook Research Institute Toronto Ontario Canada.
Alzheimer's & dementia (Amsterdam, Netherlands)
|January 15, 2025
概括
插曲性记忆测试有效地识别早期阿尔茨海默氏症 (AD) 陶在大脑中的积累. 即使在考虑大脑结构变化时,这些认知得分仍然很重要,有助于早期检测.
科学领域:
- 神经科学是一个神经科学.
- 认知心理学 认知心理学
- 医疗成像医学成像
背景情况:
- 阿尔茨海默病 (AD) 的特点是在下皮层 (ITC) 的积累.
- 识别早期AD相关的病理的敏感认知标志物至关重要.
研究的目的:
- 精确确定与ITC中定子发射断层扫描 (PET) 信号最佳相关的认知测试.
- 为了验证这些认知相关的对结构性大脑变化.
主要方法:
- 来自哈佛老化大脑研究 (HABS) 和无症状阿尔茨海默氏症 (A4) 抗粉体治疗研究的横截面数据的分析.
- 利用弹性净回归来确定ITC与PET的强有力的认知相关物.
- 对结构性大脑指标进行调整的二次分析.
主要成果:
- 包括总和"过程"分数在内的情节性记忆测量是ITC tau在两个队列中最强的相关性.
- 在控制结构性大脑体积后,这些认知相关性仍然具有统计学意义.
结论:
- 特定的情节性记忆测试得分显示,用于检测和监测早期AD神经病理学.
- 这些发现支持在早期AD研究和临床环境中使用有针对性的认知评估.
相关概念视频
Alzheimer's Disease: Overview
440
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
440
Dementia
94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
94
Alzheimer's Disease: Treatment
161
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
161


